Other substances

TMC-310911

An HIV-1 protease inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

3
 Supporting references
0
 Contradictory references
0
 AI-suggested references
2
 Clinical trials

General information

TMC-310911 on PubChem

Synonyms

ASC09; ASC-09; (3r,3As,6ar)-Hexahydrofuro[2,3-B]furan-3-Yl {(2s,3r)-4-[({2-[(1-Cyclopentylpiperidin-4-Yl)amino]-1,3-Benzothiazol-6-Yl}sulfonyl)(2-Methylpropyl)amino]-3-Hydroxy-1-Phenylbutan-2-Yl}carbamate

 

Structure image - TMC-310911

CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC5=C(C=C4)N=C(S5)NC6CCN(CC6)C7CCCC7

Supporting references

Link Tested on Impact factor Notes Publication date
Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation
3CLpro Small molecule In silico 		in silico 4.00

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Oct/19/2020
Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease
3CLpro Small molecule In silico 		in silico 1.77

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Dec/11/2020
In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors
3CLpro Small molecule In silico 		in silico 1.32

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Jan/02/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04261907 Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection Unknown status Not Applicable Feb/07/2020 Jun/30/2020
  • Alternative id - ASC09F-CTP-ZY-01
  • Interventions - Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 160
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal
NCT04261270 A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia Unknown status Phase 3 Feb/01/2020 Jul/01/2020
  • Alternative id - ASC09F-CTP-TJ-01
  • Interventions - Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Department and Institute of Infectious Disease, Wuhan, Hubei, China
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years to 55 Years   (Adult)
  • Outcome measures - Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery
Export (.csv)